NDUFAB1 and cirrhosis of liver: In a subgroup analysis regarding liver function, the mOS in the TACE cohort was (YP, IP, EP) 22 vs. 23 vs. 25 months, respectively, (p = 0.86) in patients with liver cirrhosis CPS A and 8 vs. 13 vs. 8 months, respectively, (p = 0.39) in CPS B patients (Figure 4).